Drug profile

The FDA adverse-event record for Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str

900 FDA reports name Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#196 of 2,679
by report volume (all drugs)
900
adverse-event reports
11.0%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str ranks #196 of 2679 by total reports (900) and #503 of 1130 by death-coded share (11.0%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#196
This drug, reports of 2679
#503
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str has 900 reports now versus 900 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str changes

Signature read: 900 reports place Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str in the upper third of FDA AER volume (#196 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
900
Total Reports
99
Deaths Reported
11.0%
Death-coded share of reports

Active Ingredients

Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str

Administration Routes

SubcutaneousUnknownOralSubconjunctivalNasal

Species Affected

Dog 900

Most Affected Breeds

Retriever - Labrador 70
Chihuahua 61
Terrier - Yorkshire 51
Terrier - Bull - American Pit 44
Shih Tzu 35
Shepherd Dog - Australian 35
Retriever - Golden 32
Maltese 29
Bulldog - French 28
Boxer (German Boxer) 27

Most Reported Reactions

Vomiting 388
Lethargy (see also Central nervous system depression in 'Neurological') 218
Facial swelling (see also 'Skin') 162
Anaphylaxis 126
Diarrhoea 119
Hives (see also 'Skin') 104
Pale mucous membrane 87
Fever 68
Seizure NOS 67
Not eating 62
Death 49
Anorexia 46

Outcome Breakdown

Ongoing
455 (50.4%)
Recovered/Normal
307 (34.0%)
Died
55 (6.1%)
Euthanized
45 (5.0%)
Outcome Unknown
40 (4.4%)

Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str: high report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar death-coded share

Nearest other drugs by death-coded share (11.0% here), distinct from the volume row.

Lyme 10.9% Fenbendazole 10.9% Silver Sulfadiazine 10.9% Antibacterial, Anti-Inflammatory, Antifungal 11.1%

What to do with this drug

  • Compare Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str's report volume and death-coded share against similar drugs nationwide. See similar drugs
  • Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str (#196 of 2,679 by report volume); death-coded 11.0%. PlainBreed drug row · report volume stamp 900 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →